Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hage, R.
Right arrow Articles by van den Bosch, J. M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hage, R.
Right arrow Articles by van den Bosch, J. M. M.
(Chest. 1998;114:1316-1320.)
© 1998 American College of Chest Physicians

Neural Cell Adhesion Molecule Expression

Prognosis in 889 Patients With Resected Non-small Cell Lung Cancer

René Hage MD1; Hans R. J. Elbers MD, PhD2; Aart Brutel de la Rivière MD, PhD, FCCP3; and Jules M. M. van den Bosch MD, PhD, FCCP1

1 From the department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands
2 From the department of Pathology, St. Antonius Hospital, Nieuwegein, the Netherlands
3 From the department of Thoracic Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands

J. M. M. van den Bosch, MD, PhD, FCCP, Department of Pulmonology, St. Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, the Netherlands.

Introduction: In search of factors that might predict outcome in patients with resected non-small cell lung cancer (NSCLC), we studied the reactivity of monoclonal antibody 123C3. This marker of neuroendocrine (NE) differentiation is directed against neural cell adhesion molecules (NCAM). Although NCAM can often be demonstrated in small cell lung cancer and carcinoids as a tumor antigen, not many data exist on NCAM in NSCLC.

Patients and methods: From 1983 through 1995, in 889 patients with NSCLC, who underwent pulmonary resection, 123C3 reactivity was tested. NCAM was correlated with tumor histology, p-TNM stage, and 5-year survival. Large cell NE carcinomas were excluded. Monoclonal antibody-1 (MOC-1) was also tested on most specimens.

Results: Reactivity of 123C3 does not correlate with tumor histology, p-TNM stage, or 5-year survival. In addition, MOC-1 reactivity was not significantly related to prognosis.

Conclusions: Positive reactivity with 123C3, indicating NE differentiation, does not have predictive value in NSCLC. Also, tumor histology or stage did not correlate with 123C3 reactivity. Reactivity of MOC-1 did not contribute to prediction of prognosis. Whether there is more chemosensitivity in NSCLC-NE than in NSCLC without NE differentiation remains an important question that is not addressed by our present study.

Key Words: lung cancer • NCAM • neuroendocrine differentiation • prognosis

Submitted on December 11, 1997
Accepted on May 29, 1998




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
M. R. Wick and J. H. Ritter
Neuroendocrine neoplasia of the lung
Ann. Thorac. Surg., January 1, 2000; 69(1): 307 - 308.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Chest Physicians.